Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) shares are trending on Thursday night.
Shares of the Massachusetts-based biotechnology company fell 1.24% in after-hours trading to $459.25 on Thursday despite reporting fourth-quarter revenue of $3.19 billion, up 10% year-over-year, according to a company press release.
According to Benzinga Pro data, the stock closed regular trading at $465.02, up 0.82%.
CF Portfolio Diversification Powers Earnings Growth
The revenue growth was driven by ALYFTREK, a prescription cystic fibrosis treatment for patients aged 6 and older, which generated $380.1 million for the quarter, helping to offset a decline in TRIKAFTA, the company’s CF therapy for patients aged 2 and older, which fell to $2.57 billion from $2.72 billion year-over-year.
Vertex Pharmaceuticals reported a fourth-quarter 2025 net income of $1.2 billion according to generally …